A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Treatment tested

• laquinimod 0.3
• laquinimod 0.6
• Laquinimod

Placebo or sham

• Placebo

Other measures (1)

Inclusion Criteria: 1. Willing and able to give written informed consent 2. Confirmed MS diagnosis as defined by the McDonald criteria 3. R-R MS disease course. 4. At least one gadolinium-enhanced lesion on screening MRI 5. Women of child-bearing potential must practice a reliable method of birth control. 6. Must understand the requirements of the study and agree to comply with the study protocol. Exclusion Criteria: 1. Subjects who suffer from any form of progressive MS. 2. Any condition which the investigator feels may interfere with participation in the study. 3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, 4. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening 5. Previous treatment with immunomodulators within two months prior to screening

Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute brain lesions. The duration of the current study is 36 weeks.